Machines designed to help people with sleep apnoea do not reduce the risk of heart attack or stroke, but significantly improve quality of life.
The Sleep Apnoea Cardiovascular Endpoints (SAVE) study monitored sleep apnoea patients with a pre-existing vascular disease over four years in 89 hospitals in Australia, New Zealand, India, the US, Spain and Brazil.
The study of more than 2,700 sleep apnoea sufferers with cardiovascular disease estimated 25 percent of middle-aged men and 10 percent of middle-aged women suffer from sleep apnoea.
Professor Doug McEvoy from the Adelaide Institute for Sleep Health, run by Flinders University, said the overall risk of future cardiovascular events was not improved by the treatment for sleep apnoea.
However the study did show the patients who used a CPAP machine experienced quality of life benefits including reduced snoring, reduced daytime sleepiness and better mood.
Professor Ron Grunstein from the Woolcock Institute of Medical Research in Sydney said there were "major improvements in wellbeing".
The SAVE study emphasises the benefits that apnoea sufferers receive by using CPAP machines for at least four hours during a sleep session — a finding manufacturers will be paying close attention to.